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Objectives.Toinvestigatewhetherprocalcitonin(PCT)couldbeusefulfordetectingbacterialinfectionsinpatientsonhemodialysis
(HD) and with increased calcitonin (CT). Methods. This prospective study included 42 males and 34 females on HD. The infection
group consisted of 15 patients with proven bacterial infections; the other 61 patients were designated as the noninfection group.
Serum C-reactive protein (CRP), interleukin (IL)-6, white blood cell (WBC) count, immature and total neutrophil (I/T) ratio, and
CT were measured at the beginning of HD, and serum PCT levels at the beginning of HD and after HD. Results. The mean CT level
in the both groups was apparently higher than that of nonchronic kidney disease. Signiﬁcantly higher values between the infection
and noninfection groups were seen for CRP, IL-6, WBC, I/T ratio, PCT, and CT. The PCT value of the area under the receiver
operating characteristic curve was 0.921, which was signiﬁcantly higher than the values for CRP (0.853; P<0.01), IL-6 (0.739;
P<0.01), WBC (0.692; P<0.01), and I/T ratio (0.584; P<0.01). Conclusions. PCT was useful marker of bacterial infection in
patients on HD and with increased CT. PCT levels should be determined before HD.
1.Introduction
Procalcitonin (PCT) was ﬁrst described in 1993 as a diag-
nostic marker of infection [1]. It is a polypeptide of 116
amino acids and has a molecular weight of 13kDa. The
clinical signiﬁcance of serum PCT in discriminating between
bacterial infections and nonbacterial infections, such as
systemic inﬂammatory response syndrome (SIRS), has been
comparedwiththatofothermarkersincludingendotoxin,β-
D-glucan, interleukin (IL)-6, C-reactive protein (CRP), and
white blood cell (WBC) count [2–6]. Serum PCT levels in
patients with systemic or localized bacterial infections were
signiﬁcantly higher than those in patients with nonbacterial
infections or noninfectious diseases [7]. Furthermore, PCT-
guided antibiotic therapy for respiratory tract infections has
beenshowntosigniﬁcantlydecreaseantibioticexposurewith
subsequent reduction in antibiotic-associated side eﬀects
and antibiotic resistance [8]. PCT is also an eﬀective tool
for diagnosis and risk stratiﬁcation of upper urinary tract
infections in children [9, 10]. Based on these ﬁndings,
PCT is now identiﬁed as an important marker of bacterial
infections.
PCT is the precursor molecule of human calcitonin (CT)
and is synthesized by thyroid C cells. Increased serum CT
levels have been observed in patients with chronic kidney
disease due to increased secretion of CT by thyroid C cells,
rather than decreased glomerular clearance [11, 12]. Under
conditions involving increased CT secretion, PCT may not
function as a primary marker for detection of systemic and
local bacterial infections in patients with chronic kidney
disease.
The use of PCT as a bacterial diagnostic marker is
controversial in patients on hemodialysis (HD) [13–15].
Infections account for considerable morbidity and mortality
in patients on HD [16]; hence, early diagnosis of bacterial
infections is important to make a prognostic assessment of
its severity. If PCT can be used as a primary marker for
bacterial infections in patients on HD, these infections can
be diagnosed and treated early. Therefore, we investigated2 ISRN Urology
whether PCT could function as a primary diagnostic marker
of bacterial infections in patients on HD.
We ﬁrst investigated whether PCT was useful in the
diagnosis of bacterial infections in patients with increased
serum CT levels and on HD. Furthermore, we investigated
whether serum PCT levels were inﬂuenced by HD and
determined the cut-oﬀ level of PCT in patients on HD.
2. Methods
2.1. Patient Population. The study was performed in accor-
dance with the guidelines of the Declaration of Helsinki and
was approved by the Izuhara Hospital Institutional Review
Board in the Nagasaki Prefecture. Written informed consent
was obtained from all patients. The study included 42 male
and 34 female patients (median age 69 years, range 28–86)
who underwent HD between April 2008 and March 2009.
Thepatientsweredividedinto2groupsonthebasisofadiag-
nostic work up. The ﬁrst group (Infection group) included
patients with conﬁrmed systemic or localized (pneumonia
or arteriovenous graft infection) bacterial infections. With
or without positive sputum culture results, patients with
pneumonia were deﬁned as those with clinical signs and
symptoms suggestive of lower respiratory infections, those
showing consolidation on a plain chest radiograph. Bacterial
infection involving an arteriovenous graft was diagnosed
as a subcutaneous abscess associated with tenderness with
positive bacterial culture results. Systemic bacterial infection
was diagnosed in patients with high fever and positive blood
culture results. The second group (noninfection group)
included patients without suspicion of having an infection,
and we selected randomly the control group consist of
routine HD patients.
2.2. Laboratory Examinations. Serum CT, CRP, IL-6, WBC
count, and immature and total neutrophil (I/T) ratio were
measured at the beginning of HD. Serum PCT levels were
measured at the beginning and 4h after HD. HD was
performed using high-ﬂux membranes such as ethylene
vinyl alcohol copolymer and polymethyl methacrylate mem-
branes.
2.2.1. PCT. Serum PCT levels in patients was determined by
an electrochemiluminescence immunoassay (Procalcitonin
Kit, Roche Diagnostics GmbH, Mannheim, Germany) that
had a lower detection limit of 0.02ng/mL. Levels below
this detection limit were classiﬁed as “zero.” The intra-assay
coeﬃcient of variation was <10%. Two days were needed for
a PCT measurement.
2.2.2. CRP. CRP was measured by a latex agglutination
method (C-Reactive Protein Kit, A&T Corporation, Kana-
gawa, Japan) that had a lower detection limit of 0.02mg/L
and an intra-assay coeﬃcient of variation was <10%.
2.2.3. IL-6. IL-6 was measured by a chemiluminescent
enzyme immunoassay (Human IL-6 CLEIA, Fujirebio Inc.,
Tokyo, Japan) that had a lower detection limit of 0.2pg/mL.




group (N = 61) P value
Age 65.1 ±14.96 5 .7 ±12.6N . S
Gender (M: 10, F: 5) (M: 32, F: 29) N.S
Localized infection




No identiﬁable source 1 0 —
M: male; F: female. The data are expressed as the mean ± SD.
2.2.4. WBC Count and I/T Ratio. WBC count and I/T
ratio were measured using a multiparameter automated
hematology analyzer designed for in vitro diagnostic use to
count and characterize blood cells (CELL-DYN Sapphire,
Abbott Laboratories, Abbott Park, IL, USA).
2.2.5. CT. CT was measured by a radioimmunoassay (Cal-
citonin Kit, Mitsubishi Chemical Medicine Corporation,
Tokyo, Japan) that had a lower detection limit of 12.5pg/mL
and an intra-assay coeﬃcient of variation was <10%.
2.3. Statistical Analysis. The Mann-Whitney U test was used
to compare the groups, while receiver operating characteris-
tic (ROC) analysis was performed to evaluate the ability of
PCT to discriminate between the 2 groups.
PCT levels at the beginning and after HD were compared
using the Wilcoxon matched-pairs test. P<0.05 was
considered statistically signiﬁcant. The data were expressed
as mean ± standard deviation.
3. Results
The diagnostic work up identiﬁed 15 patients (10 males and
5 females, mean age 65.1±14.9 years) with conﬁrmed infec-
tions.Fourteenofthemhadlocalizedbacterialinfectionsand
negative blood culture results. The localized infections were
as follows: 13 patients had lower respiratory tract infections
and 1 had bacterial infection involving an arteriovenous
graft. One patient had systemic bacterial infection with
positive blood culture results, and the patients had no
identiﬁable source of infection. The remaining 61 patients
selected randomly from routine HD patients (32 males and
29 females, mean age 65.7 ± 12.6 years), without suspicion
of having an infection, were designated as the noninfection
group. Signiﬁcant diﬀerences in age and gender between the
2gr o u p sw e r ea b s e n t( Table 1). However, the infection group
had signiﬁcantly higher PCT (P<0.01), CRP (P<0.01),
and IL-6 (P<0.01) levels, WBC counts (P<0.01), and
I/T ratio (P = 0.05) than the noninfection group (Figure 1).
The mean CT level in patients of both groups was apparently
higher than that in patients with nonchronic kidney disease
[17]. Furthermore, the mean CT level in the infection group
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Figure 1: Comparisonofbox plotsofclinical parameters beforehemodialysisbetween theinfectionandnoninfectiongroups.(1)PCTlevels
(∗P<0.01), (2) CRP levels (∗P<0.01), (3) IL-6 (∗P<0.01) levels, (4) WBC count (∗P<0.01), (5) I/T ratio (∗∗P = 0.05), and (6) CT levels
(∗P<0.01) were signiﬁcantly higher in the Infection group than those in the Noninfection group. PCT: procalcitonin; CT: calcitonin; CRP:
C-reactive protein; IL-6: interleukin-6; WBC: white blood cells; I/T ratio: immature and total neutrophil ratio; I: infection; NI: noninfection.4 ISRN Urology
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(P<0.01) (Figure 1). A signiﬁcant correlation was absent
between PCT and CT levels in the Infection group but
present in the Noninfection group (Table 2). In order to
evaluate the various tests for discriminating between the 2
groups, area under the ROC curve (AUC) was calculated for
each biomarker (Figure 2). AUC for PCT was 0.921, which
was signiﬁcantly higher than that for CRP (0.853; P<0.01),
IL-6 (0.739; P<0.01), WBC (0.692; P<0.01), and I/T ratio
(0.584; P = 0.05). Using 0.5ng/mL as the designated cut-
oﬀ PCT level, the sensitivity and speciﬁcity were found to be
86.7% and 96.7%, respectively.
HD was performed using high-ﬂux membranes in all
patients. PCT levels before and after HD were measured in
6 5p a t i e n t s .T h em e a nP C Tl e v e lb e f o r eH Dw a s0 . 2 7n g / m L
and that after HD was 0.22ng/mL. Figure 3 shows that PCT
levels decreased signiﬁcantly after HD (P<0.01).
4. Discussion
Many investigators have reported that PCT is the most
sensitive marker of bacterial infection [2–7]. Furthermore,
Schuetz et al. reported that PCT-guided antibiotic therapy
for respiratory tract infections can signiﬁcantly reduce
antibiotic exposure [8]. Recently, PCT was used not only as
a marker of systemic bacterial infection but also as a marker
of local bacterial infection. However, Dahaba et al. proposed
that CRP, which is not aﬀe c t e db yH D ,m a yb eau s e f u l
markerofsepsisinHDpatientswhohavereducedPCTlevels
because of HD [15] .T h eu s eo fP C Ta sad i a g n o s t i cm a r k e r
of bacterial infections has been controversial in patients
on HD. Bacterial infections are a major cause of mortality
in patients on HD as these patients are often clinically
compromised [16]. Therefore, it is important to diagnose
bacterial infection at an early stage to improve prognosis.
Increased CT synthesis in thyroid C cells has been
observed in patients on HD. Therefore, since PCT is the
precursor molecule of CT, it is believed that PCT synthesis
would also be increased. However, the relationship between
PCT and CT in patients on HD has not been reported.
Because of increased CT synthesis in thyroid C cells in
patients on HD, we believe that PCT cut-oﬀ levels for
indicating bacterial infection in these patients may be higher
than those in patients without chronic kidney disease.
In this study, mean CT level in patients of both groups
was higher than that in patients with nonchronic kidney
disease [17]. However, we demonstrated that PCT was the



























6, WBC, and I/T ratio. The area under the curve for PCT (0.921)
was signiﬁcantly higher than those for CRP (0.853; P<0.05),
IL-6 (0.739; P<0.01), WBC (0.692; P<0.01), and I/T ratio
(0.584; P = 0.05). PCT: procalcitonin; CRP: C-reactive protein; IL-
6: interleukin-6; WBC: white blood cell count; I/T ratio: immature




















Figure 3: PCT levels before and after hemodialysis (HD). PCT
levels decreased signiﬁcantly after HD. The pre- and postHD
measurements were compared using the Wilcoxon matched-pairs
test. PCT: procalcitonin; preHD: before performing hemodialysis;
postHD: after performing hemodialysis for 4h.
from nonbacterial infections including those in patients on
HD. The cut-oﬀ level for PCT was approximately 0.5ng/mL,
a value similar to that reported in a previous study on
patients without chronic kidney disease [18, 19]. Serum
PCT levels may increase under many conditions associated
with SIRS, even in the absence of a thyroid gland [20].
Furthermore,PCTissynthesizedinthesmallintestine,lungs,
and liver in patients with bacterial infections [21, 22]. In
the noninfection group, PCT was synthesized in the thyroid
gland alone, thus, explaining the signiﬁcant correlation
between PCT and CT levels. However, it can be synthesized
in the thyroid gland as well as in other organ such as lung inISRN Urology 5
responsetobacterialinfections.PCTsynthesizedinlungmay
notbeconvertedtoCTbecauseconversioncanbeperformed
only by thyroid C cells. In other words, PCT that cannot be
convertedtoCTmaybeincreasedduringbacterialinfections.
As a result, we observed no signiﬁcant correlation between
PCT and CT in the infection group, with the correlation
coeﬃcient being similar in both groups in our study. In cases
that showed higher PCT levels in the infection group, it may
be believed that there would be a signiﬁcant diﬀerence in the
correlation coeﬃcient between the 2 groups.
If PCT level is aﬀected by HD, its measurement will
not provide an accurate diagnosis and prognostic assessment
of bacterial infection. Therefore, we investigated the eﬀect
of HD on PCT levels. In this study, PCT levels apparently
decreased after HD using high-ﬂux membranes, indicating
that they are inﬂuenced by HD using high-ﬂux membranes
[23]. However, because low-ﬂux membranes were not used
in our study, we could not determine the eﬀect of HD
using low-ﬂux membranes on PCT levels. When patients on
HD using high-ﬂux membranes develop bacterial infections,
PCT levels immediately before HD should be investigated.
In addition, in experimental sepsis, mortality is decreased by
antiserum to PCT [24]. Therefore, elimination of PCT by
HD using high-ﬂux membranes may decrease mortality in
patients with bacterial infections.
We investigated the use of PCT as a diagnostic marker
of infection only in patients on HD. However, PCT has
recently been identiﬁed as a marker of inﬂammation and has
been recommended as a potential new marker of peritonitis
in patients on continuous ambulatory peritoneal dialysis
(CAPD)[25,26].CAPDpatientsalsoshowincreasedCTand
PCT synthesis in thyroid C cells because of chronic kidney
disease. The results of these investigations on CAPD patients
are concurrent with the results of the present study.
5. Conclusion
PCT was a very good marker of bacterial infection even in
patients with increased CT levels undergoing HD. PCT levels
should be determined before HD since the levels can be
aﬀectedbyhigh-ﬂuxmembranes.Furthermore,thePCTcut-
oﬀ level that indicates a bacterial infection should be set at
0.5ng/mL in HD patients.
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